Impact of Tumor Location on Survival Outcomes in Pancreatic Head Versus Body/Tail Cancer: Institutional Experience
Cancers · 26.05.2025 · 17 (11) · 1777
DOI: 10.3390/cancers17111777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 26.05.2025. Verfasst von Abdullah Esmail und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section of GI Oncology, Department of Medicine, Houston Methodist Neal Cancer Center, Houston, TX 77030, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDAC) exhibits variable survival outcomes based on tumor location, with pancreatic head cancer (PHC) and pancreatic body/tail cancer (PBTC) differing in prognosis and treatment response. This study investigates the correlation between tumor location and survival outcomes in PDAC patients treated with standard chemotherapy regimens.
Methods
A retrospective analysis of 604 PDAC patients (400 PHC, 204 PBTC) diagnosed between January 2015 and May 2024 at Houston Methodist Neal Cancer Center was conducted. Patients received either mFOLFIRINOX or gemcitabine/nab-paclitaxel as first-line therapy. Clinical data, including demographics, tumor stage, treatment modalities, and molecular profiles, were extracted from electronic records. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan–Meier analyses and Cox proportional hazards models. Latent class analysis (LCA) identified patient subgroups based on shared clinical, demographic, and survival characteristics.
Results
PHC patients demonstrated superior median OS (12 months) compared to PBTC (9 months, p = 0.012) and PFS (8 months vs. 5 months, p = 0.0008). Across both subtypes, mFOLFIRINOX was associated with significantly longer OS than gem/nab-paclitaxel (PHC: 18.8 vs. 12.7 months, p < 0.0001; PBTC: 14 vs. 6 months, p = 0.011). LCA revealed distinct clusters: in PHC, a curative-intent class (median OS > 24 months) contrasted with a palliative class ( 18 months) differed from a limited treatment class (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of GI Oncology, Department of Medicine, Houston Methodist Neal Cancer Center, Houston, TX 77030, USA.
- Department of Medicine, King Saud University Medical City, Riyadh 12372, Saudi Arabia.
- Department of Medicine, King Fahd Specialist Hospital, Dammam 32253, Saudi Arabia.
- Faculty of Medicine, The University of Jordan, Amman 11942, Jordan.
ORCID-Profile: Abdullah Esmail
Zitieren
APA
Esmail, A., Dhillon, V., Al-Najjar, E., Khasawneh, B., Alghamdi, M., Ibnshamsah, F., & Abdelrahim, M. (2025). Impact of Tumor Location on Survival Outcomes in Pancreatic Head Versus Body/Tail Cancer: Institutional Experience. Cancers, 17(11), 1777. https://doi.org/10.3390/cancers17111777
Vancouver
Esmail A, Dhillon V, Al-Najjar E, Khasawneh B, Alghamdi M, Ibnshamsah F, et al. Impact of Tumor Location on Survival Outcomes in Pancreatic Head Versus Body/Tail Cancer: Institutional Experience. Cancers. 2025;17(11):1777. doi:10.3390/cancers17111777
BibTeX
@article{Esmail2025,
author = {Esmail, Abdullah and Dhillon, Vikram and Al-Najjar, Ebtesam and Khasawneh, Bayan and Alghamdi, Mohammed and Ibnshamsah, Fahad and Abdelrahim, Maen},
title = {Impact of Tumor Location on Survival Outcomes in Pancreatic Head Versus Body/Tail Cancer: Institutional Experience},
journal = {Cancers},
year = {2025},
volume = {17},
number = {11},
pages = {1777},
doi = {10.3390/cancers17111777}
}
EUVIMED